We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

GLP-2 (Glucagonlike Peptide-2) and Blood Flow

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00540215
Recruitment Status : Completed
First Posted : October 5, 2007
Last Update Posted : February 11, 2011
Information provided by:

Study Description
Brief Summary:

It is the study aim to investigate the effect of glp-2 on blood flow in humans. we wish to study eventual changes in renal blood flow, carotic blood flow and cardiac out put.

GLP-2 will be administered subcutaneously, and the effect monitored by doppler ultra sound scannings and cotinuesly measuring of cardiac out put and blood pressure.

The study will include 15 healhty volunteers, 10 wil receive 450 nmol GLP-2 and 5 will receive 1 ml of isotonic saline (as baseline reference).

Condition or disease Intervention/treatment
Regional Blood Flow Other: Glucagonlike peptide

Detailed Description:
se the above

Study Design

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 15 participants
Intervention Model: Single Group Assignment
Masking: Single (Participant)
Primary Purpose: Basic Science
Official Title: The Role of GLP-2 in Univercal Changes in Blood Flow in Humans
Study Start Date : October 2007
Primary Completion Date : January 2008
Study Completion Date : February 2008
Arms and Interventions

Arm Intervention/treatment
Active Comparator: 1
450 nmol GLP-2 SC
Other: Glucagonlike peptide
450 nmol native form, synthetic
Placebo Comparator: 2
1 ml isotonic saline SC
Other: Glucagonlike peptide
450 nmol native form, synthetic

Outcome Measures

Primary Outcome Measures :
  1. effect of glp-2 [ Time Frame: during study ]

Secondary Outcome Measures :
  1. potential new ideas for further studies [ Time Frame: months to years ]

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   20 Years to 60 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Age 20-60
  • Healthy
  • No medication
  • Not pregnant

Exclusion Criteria:

  • All of the persons not meeting the abowe mentioned criteria
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00540215

Glostrup University Hospital
Glostrup, Region Hovedstaden, Denmark, 2600
Sponsors and Collaborators
Glostrup University Hospital, Copenhagen
Principal Investigator: lasse bremholm, MD Glostrup university hospital
More Information

ClinicalTrials.gov Identifier: NCT00540215     History of Changes
Other Study ID Numbers: H-D-2007-0050
First Posted: October 5, 2007    Key Record Dates
Last Update Posted: February 11, 2011
Last Verified: October 2007